All In Biotech

Drug Trial Radar · NCT05663593

Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers

A Randomised, Double-blind, Placebo-controlled, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Oral Doses of HSK31858 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Feb 23, 2022

Primary completion

Aug 15, 2022

Study completion Nov 30, 2022

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I, randomised, double-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HSK31858 in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

  • HSK31858, tabletDrug

    Starting dose in single ascending dose: 5 mg

  • Placebo, tabletDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs)Time frame: 7 days after single dose
  2. The number and severity of treatment emergent adverse events (TEAEs)Time frame: 56 days after multiple dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PKUCare Luzhong Hospital

    Zibo, Shang Dong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.